Apimeds Pharmaceuticals US reported revenue of $0.28M and net income of -$20.17M for the quarter ended Jun 2026. This income statement covers 10 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.46M | 0.79M | 0.79M | 0.79M | 0.79M | 0.79M | 1.04M | 1.26M | 1.26M | 1.51M |
| Revenue & cost | ||||||||||
| Revenue | 0.28M | |||||||||
| Operating items | ||||||||||
| Research & DevelopmentR&D | 0.65M | 0.62M | 0.36M | 0.96M | ||||||
| Selling, General & AdministrativeSG&A | 0.27M | 0.43M | 0.30M | 0.28M | 0.36M | 2.01M | 1.22M | 6.68M | 5.32M | |
| Operating ExpensesOpex | 0.27M | 0.43M | 0.30M | 0.28M | 0.36M | 2.66M | 1.84M | 7.04M | 6.28M | |
| Operating IncomeOp. Inc | -0.27M | -0.43M | -0.30M | -0.28M | -0.36M | -2.66M | -1.84M | -7.04M | -6.28M | |
| EBIT | -0.27M | -0.43M | -0.30M | -0.28M | -0.36M | -2.66M | -1.84M | -7.04M | -6.28M | |
| Non-operating items | ||||||||||
| Non Operating Interest Expenses | 0.03M | 0.02M | 0.03M | 0.04M | 0.04M | 0.02M | 0.01M | 0.22M | 3.22M | |
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 517.00 | 116.00 | 30.00 | 3.00 | 0.02M | 0.06M | 0.04M | 0.02M | |
| Other Non Operating IncomeOther Non Op Inc. | 458.00 | |||||||||
| Non Operating IncomeNon Op. Inc. | -0.02M | -0.02M | -0.03M | -0.04M | -0.04M | 0.00M | 0.06M | 5.88M | -13.89M | |
| Net income details | ||||||||||
| EBT | -0.30M | -0.45M | -0.33M | -0.31M | -0.40M | -2.67M | -1.79M | -7.22M | -9.48M | |
| Profit After TaxPAT | -0.30M | -0.45M | -0.33M | -0.31M | -0.40M | -2.66M | -1.78M | -1.16M | -20.17M | |
| Income from Continuing OperationsIncome (Continuing) | -0.30M | -0.45M | -0.33M | -0.31M | -0.40M | -2.67M | -1.79M | -7.22M | -9.48M | |
| Consolidated Net IncomeConsol Net Inc. | -0.30M | -0.45M | -0.33M | -0.31M | -0.40M | -2.67M | -1.79M | -7.22M | -9.48M | |
| Income towards Parent CompanyParent Net Inc | -0.30M | -0.45M | -0.33M | -0.31M | -0.40M | -2.67M | -1.79M | -7.22M | -9.48M | |
| Net Income towards Common StockholdersNet Income | -0.30M | -0.45M | -0.33M | -0.31M | -0.40M | -2.67M | -1.79M | -7.22M | -9.48M | |
| Additional items | ||||||||||
| EPS (Basic) | -0.38 | -0.57 | -0.42 | -0.39 | -0.51 | -2.58 | -1.43 | -6.63 | -5.53 | |
| EPS (Diluted) | -0.38 | -0.57 | -0.42 | -0.39 | -0.51 | -2.58 | -1.43 | -6.63 | -5.53 | |
| Shares Outstanding | 0.46M | 0.79M | 0.79M | 0.79M | 0.79M | 0.79M | 1.04M | 1.26M | 1.09M | 1.71M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.79M | 0.79M | 0.79M | 0.79M | 0.79M | 1.04M | 1.26M | 1.09M | 1.71M | |
| EBITDA | -0.27M | -0.43M | -0.30M | -0.28M | -0.36M | -2.66M | -1.84M | -7.04M | -6.28M | |
| Interest ExpensesInt Expense | 0.03M | 0.02M | 0.03M | 0.04M | 0.04M | 0.02M | 0.01M | 0.22M | 3.22M |